Analysts’ Weekly Ratings Updates for Blueprint Medicines (BPMC)
A number of research firms have changed their ratings and price targets for Blueprint Medicines (NASDAQ: BPMC): 5/2/2025 – Blueprint Medicines was upgraded by analysts at StockNews.com from a “sell” rating to a “hold” rating. 5/2/2025 – Blueprint Medicines had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $135.00 price […]
A number of research firms have changed their ratings and price targets for Blueprint Medicines (NASDAQ: BPMC): 5/2/2025 – Blueprint Medicines was upgraded by analysts at StockNews.com from a “sell” rating to a “hold” rating. 5/2/2025 – Blueprint Medicines had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $135.00 price […]
